Key result
Initial NOAC use for isolated distal DVT matches proximal DVT at ~56%.
Why the study?
Isolated distal deep vein thrombosis is presumed to be more benign than proximal DVT or pulmonary embolism, suggesting a need for different management approaches.
Does the clinical profile and real-world anticoagulant management of isolated distal DVT differ from proximal DVT or pulmonary embolism?
Population
5,772 patients with VTE across 34 countries
Comparison
IDDVT vs PDVT ± DDVT vs PE ± DVT
Design
Subgroup analysis of a global observational study
Authors
Loading...
Similar NOAC use for isolated distal DVT despite benign profile warrants caution; leaves open optimal strategies pending randomized trials.
Observational (n=5,772)
Yes
Does the clinical profile and real-world anticoagulant management of isolated distal DVT differ from proximal DVT or pulmonary embolism?
Absolute Event Rate: 55.6% vs 54.7%
In real-world practice, patients with isolated distal DVT receive anticoagulant therapy at similar rates to those with proximal DVT or PE, despite having a more benign clinical profile and fewer risk factors.
Schellong et al. (2021) conducted an observational in Acute venous thromboembolism (isolated distal DVT, proximal DVT, or pulmonary embolism) (n=5,772). Anticoagulant therapy vs. Proximal DVT or Pulmonary Embolism was evaluated on Use of non-vitamin K antagonist oral anticoagulants at hospital discharge or 14 days after diagnosis. Initial anticoagulant therapy for isolated distal deep vein thrombosis was almost equal to that for proximal deep vein thrombosis, with 55.6% and 54.7% of patients receiving NOACs, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: